Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.

The aim of this study was to investigate the clinical pharmacokinetics of 5-fluorouracil (5-FU) and its major metabolite 5-fluoro-5,6-dihydrouracil (5-FDHU) in 20 colorectal cancer patients given two dose levels of 5-FU, 250 and 370 mg/m2, administered by i.v. bolus. A reverse-phase high-performance liquid chromatographic method was used for the simultaneous assay of 5-FU and 5-FDHU in plasma samples obtained at baseline and at multiple time points from 5 min to 4 h after 5-FU bolus as well as to assess the activity of dihydropyrimidine dehydrogenase (DPD) in peripheral blood mononuclear cells (PBMCs) before 5-FU dosing. Plasma pharmacokinetic parameters of patients given 250 mg/m2 5-FU were significantly different from those receiving 370 mg/m2; main differences were observed in the trapezoidal areas under the plasma levels-versus-time curve from to to the last measurable concentration (area under the curve, 3.77+/-0.21 versus 13.61+/-2.3 h x microg/ml), peak plasma concentration (Cmax, 18.15+/-1.35 versus 48.41+/-7.69 microg/ml), and total body clearance (CL(TB), 54.64+/-3.54 versus 25.43+/-2.3 l/h/m2). Significant differences were also observed in the main pharmacokinetic parameters of 5-FDHU after 250 and 370 mg/m2 5-FU including the area under the curve from to to 4 h (5.39+/-0.32 versus 8.75+/-1.24 h x microg/ml), Cmax (3.60+/-0.16 versus 5.26+/-0.55 microg/ml) and time to Cmax (Tmax, 0.45+/-0.03 versus 0.69+/-0.06 h). The mean DPD activity in PBMCs in this group of patients was 205.7+/-36.4 pmol of 5-FDHU/min/mg of protein and was within the normal range; however, no significant correlations were found between 5-FU or 5-FDHU pharmacokinetic parameters at two dose levels and DPD activity of PBMCs. The results of the present study provide the first detailed comparison of the distribution of 5-FU and its major metabolite 5-FDHU at the therapeutic level as well as at reduced test dose levels to obtain pharmacokinetic data to be used as reference values for the identification of patients at risk of major 5-FU toxicity due to impaired metabolism to 5-FDHU.

[1]  R. Dedrick,et al.  Nonlinear pharmacokinetic models for 5‐fluorouracil in man: Intravenous and intraperitoneal routes , 1980, Clinical pharmacology and therapeutics.

[2]  F. Gonzalez,et al.  Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. , 1995, Trends in pharmacological sciences.

[3]  P. Vreken,et al.  Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W , 1997, Human Genetics.

[4]  J. Fourtillan,et al.  Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Diasio,et al.  Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. , 1988, The Journal of clinical investigation.

[6]  R. Diasio,et al.  Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Robert B. Diasio,et al.  Clinical Pharmacology of 5-Fluorouracil , 1989, Clinical pharmacokinetics.

[8]  H. McLeod,et al.  Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. , 1996, The Journal of clinical investigation.

[9]  J. Sludden,et al.  Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. , 1998, British Journal of Cancer.

[10]  G. Milano,et al.  Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. , 1995, The American journal of medicine.

[11]  F Demard,et al.  Population study of dihydropyrimidine dehydrogenase in cancer patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Sludden,et al.  Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. , 1998, British Journal of Cancer.

[13]  Martin R. Johnson,et al.  Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[14]  A. B. Kuilenburg,et al.  Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients , 1999, British Journal of Cancer.

[15]  U. Veronesi,et al.  Oxford textbook of oncology , 1996 .

[16]  G. Milano,et al.  Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits. , 1996, Therapeutic drug monitoring.

[17]  R. Diasio,et al.  Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. , 1987, Cancer research.

[18]  G. Peters,et al.  Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. , 1988, Cancer research.

[19]  J. Robert,et al.  Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Venzon,et al.  Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells , 1997, Cancer Chemotherapy and Pharmacology.

[21]  D. Machover.  A comprehensive review of 5‐fluorouracil and leucovorin in patients with metastatic colorectal carcinoma , 1997, Cancer.